The release of [3Hlnorepinephrine from isolated mouse vas deferens has been measured. 1-Phenylephrine and 1-norepinephrine significantly enhanced the spontaneous release of radioactivity. As shown by a combination of HPLC and scintillation spectrometry, the release of total radioactivity in response to 1-phenylephrine or 1-norepinephrine consisted mainly of [3H]norepinephrine. Evidence has been obtained that the release of endogenous norepinephrine by exogenous norepinephrine and 1-phenylephrine is independent ofthe external Ca2' concentration. The released endogenous norepinephrine in turn inhibits the release of norepinephrine in response to electrical field stimulation. In the presence of yohimbine, the enhancement of spontaneous release due to 1-phenylephrine (or to 1-norepinephrine) was not affected, whereas there was a significant superimposed release of [3H]norepinephrine in response to field stimulation, indicating that the inhibition of stimulation-induced norepinephrine release is an a2-adrenoceptor-mediated process. An important consequence of these findings is to question previous interpretations that the effects of administration of 1-norepinephrine or 1-phenylephrine are due exclusively to their direct effects on the effector cells. The Ca-independent release of endogenous norepinephrine might partly initiate their pharmacological responses. It is concluded that this Ca-independent release is of functional importance, since norepinephrine may accumulate in a concentration sufficient to modulate the release of norepinephrine from varicosities in response to electrical stimulation.
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It is generally accepted (1) that 1-norepinephrine and 1-phenylephrine act directly on effector cells, rather than indirectly, via release of endogenously stored substances. However, in previous studies, evidence has been obtained that sympathomimetic amines can release norepinephrine from various tissues (2) (3) (4) (5) (6) (7) (8) (9) (10) . In spite of this evidence, it has been concluded that the contribution of this indirectly mediated release to the pharmacological effects of, for example, 1-phenylephrine is negligible (5, 8) .
In the present study, an attempt was made to determine whether endogenous norepinephrine released by the addition of 1-norepinephrine, or the a1-adrenoceptor agonist, 1- phenylephrine, could be involved in the presynaptic modulation of further norepinephrine release evoked by axonal stimulation. Neurochemical evidence has been obtained that the endogenous norepinephrine released in a Ca-independent manner by 1-phenylephrine or 1-norepinephrine inhibits the release ofnorepinephrine in response to electrical stimulation via an a2-adrenoceptor mediated mechanism. 3 -min fractions were collected. The radioactivity released was measured as described by Vizi et al. (11) . The amount (820,600 ± 25,200 Bq/g, n = 22) of radioactivity was also measured (11) at the end of the experiment.
EXPERIMENTAL PROCEDURES
Evoked release was defined as the tritium (Bq/g) in excess of that of resting outflow in samples during and following stimulation. To quantify the effects of drugs on stimulationevoked release of tritium, the evoked release in the presence of the drug (S2) was divided by the release evoked by stimulation prior to inclusion of the drug (S1). Drugs were added to the superfusion medium 21 min before S2. To quantify the effect of drug on spontaneous release, the fractional release in the 3 min before S2 (Sp2) was divided by the fractional release in the 3-min period before Si (Sp,). The Sp2/Sp1 ratio reflects the prestimulation (spontaneous) efflux of radioactivity in the presence of drug (Sp2) divided by the prestimulation efflux in the absence of the drug (Sp,).
Electrical field stimulation was applied (10 V/cm, 1 ms) at 1 Hz frequency as described by Paton and Vizi (12) .
Reverse-Phase HPLC Combined with Electrochemical and Radiochemical Detection. The HPLC system (Biotronik Wissentschaftliche Gerate, Frankfurt am Main, F.R.G.) was used as described (11 RESULTS Release of Radioactivity Evoked by l-Norepinephrine and 1-Phenylephrine. After 120 min ofperfusion, the spontaneous efflux of radioactivity measured in 3-min samples from isolated mouse vasa deferentia loaded with [3H]norepinephrine had become low and stable, representing 0.2-0.6% ofthe radioactivity remaining in the tissue. Electrical field stimulation with 1 Hz (180 -shocks) increased the release (Si) of radioactivity by 3082 ± 292 Bq/g (n = 6) above the spontaneous level. When the stimulation was repeated 41 min later (S2), the amount of radioactivity (2996 ± 197 Bq/g, n = 6) did not differ significantly from that evoked by the first stimulation (P > 0.05, Student's t test). The ratio S2/S1 was 0.98 ± 0.11 (n = 6). That the release was subject to presynaptic modulation was demonstrated by finding that yohimbine, an a2-adrenoceptor antagonist, enhanced the S2/S1 ratio to 3.25 ± 0.21 and xylazine, an a2-agonist, reduced this ratio by >80%o (Table 1) . 1-Norepinephrine produced a nearly complete inhibition of the stimulation-induced release. The S2/S1 ratio in the presence of 1 ,AM 1-norepinephrine was 0.08 + 0.02 (n = 6). In contrast, the spontaneous release was enhanced by 1-norepinephrine; there was a 3.38-fold increase in the release of radioactivity. Table 1 shows that, although the stimulation-evoked release was Ca dependent, the effect of 1-norepinephrine on spontaneous release was Ca independent. The release evoked by 1-norepinephrine proved to be tetrodotoxin insensitive (Fig. 1) . A similar observation was made with 1-phenylephrine (10 uM). The question arises as to whether or not the norepinephrine released from endogenous stores in a Ca-independent manner is of functional importance-i.e., whether it is involved in the presynaptic modulation of norepinephrine release.
Effect ofnorepinephrine. The effect of 1-norepinephrine on the spontaneous and evoked release of radioactivity is shown in Fig. 2A . While 1-norepinephrine significantly enhanced the fractional spontaneous release of radioactivity (from 2.2 ± 0.05 x 10-per 3 min to 8.41 ± 0.07 x i0-3 per 3 min), it completely inhibited the effect of electrical stimulation ( Fig.  2A) . However, in the presence of yohimbine and 1-norepinephrine together (Fig. 2B) radioactivity released by the superimposed outflow and that evoked by stimulation in the absence of 1-norepinephrine plus yohimbine was significantly higher (P < 0.01, Student's t test) than in controls (0.97 ± 0.11, Table 1 ). These data show that 1-norepinephrine (10 AM) causes an efflux of radioactivity that represents the release of stored norepinephrine and that it inhibits the effect of electrical stimulation via a2-adrenoceptor stimulation, but they do not elucidate the role of norepinephrine-released endogenous norepinephrine in the presynaptic modulation ofnorepinephrine release. Clearly, it is not possible to distinguish between the effect ofnorepinephrine derived from endogenous stores and the effect of that added to the medium. It is generally accepted that 1-phenylephrine has no significant a2-adrenoceptor stimulant activity (15) (16) (17) . Therefore it seemed that 1-phenylephrine might be useful to clarify the role of endogenous norepinephrine released in a Ca-independent way of presynaptic modulation.
Effect ofl -phenylephrine. The effect of 1-phenylephrine on (Fig.  3B ) on spontaneous release (18.38 ± 2.00 x 10-3 per 3 min) but, in its presence, electrical stimulation released a large amount of radioactivity. In the presence of yohimbine plus 1-phenylephrine the release of radioactivity (13600 ± 2500 Bq/g; n = 3) in response to electrical stimulation was significantly higher (P < 0.01, Student's t test) than that in the absence of drugs (3150 ± 405 Bq/g; Fig. 3B ). In the presence of yohimbine, the response to stimulation was superimposed on the enhanced spontaneous efflux of radioactivity.
Evidence (20), an attempt was made to study the effects of 1-norepinephrine and 1-phenylephrine on [3H]norepinephrine release in tissue that had been pretreated with reserpine and pargyline (to inhibit monoamine oxidase)-i.e., tissue in which the [3H]norepinephrine is exclusively located in the cytoplasm (21) . Under these conditions the resting release was significantly higher (16.3 ± 0.89 x 10-3 per 3 min; n = 3; P < 0.01), and 1-norepinephrine (10 uM) and 1-phenylephrine (10 juM) enhanced the fractional release of radioactivity (from 16.1 + 0.9 X 10-3 to 26.6 ± 0.64 x 10-3 and from 15.31 ± 0.88 x 10-3 to 25.30 ± 0.31 x 10-3 per 3 min, respectively; for both cases, P < 0.01; n = 3). Electrical stimulation (1 Hz, 180 shocks) did not enhance the release. Although favorable conditions for filling the axoplasmic space with [3H]norepinephrine prevailed (inhibition of vesicular uptake and blockade of monoamine oxidase activity), the release evoked by 1-norepinephrine or 1-phenylephrine in the tissue was less than the release evoked by 1-norepinephrine or 1-phenylephrine from vas deferens obtained from nontreated mouse.
DISCUSSION
Although previous studies have shown that 1-phenylephrine can release norepinephrine (4, 5, 8, 9) , little attention has been paid to this phenomenon. 1-Phenylephrine has been considered as a direct acting a1-adrenoceptor agonist (16) . In addition, evidence has been obtained that radioactivity can be released by other sympathomimetic amines from heart that has been loaded with [3H]norepinephrine (2-4, 6, 10, 22, 23) . However, no evidence has been found that the released radioactivity is due mainly to [3H]norepinephrine. In this study, we have found that 1-norepinephrine and 1-phenylephrine are able to release radioactivity from isolated mouse vas deferens. A combination of reverse-phase HPLC and scincillation spectrometry showed that the released radioactivity induced by 1-norepinephrine or 1-phenylephrine is due to the release of [3H]norepinephrine and not to 3H-labeled metabolites. Evidence has been obtained that 1-norepinephrine (10 ,.M) produces an -30-fold increase in endogenous norepinephrine release, which does not depend on the presence of Ca in the bathing fluid. Similarly, the release by tyramine (24) is also Ca independent. Although the stimulation-evoked release of [3H]norepinephrine requires external Ca, the release evoked by 1-norepinephrine or 1-phenylephrine is independent of the external Ca2' concentration. In addition, evidence has been obtained that the mechanism of release by 1-norepinephrine (1-phenylephrine) is different from that induced by electrical stimulation. In reserpine-treated tissue containing a monoamine oxidase inhibitor, in which [3H]norepinephrine is located in the cytoplasm (21), 1-norepinephrine and 1-phenylephrine released radioactivity but electrical stimulation did not. Therefore, it seems likely that 1-norepinephrine-and 1-phenylephrine-evoked release is of cytoplasmic origin. A similar mechanism has been suggested by Trendelenburg (25) regarded as a pure direct-acting a1-adrenoceptor agonist, provides convincing evidence that endogenous norepinephrine released in a manner that is independent of the external Ca concentration may be involved in presynaptic modulation. Thus, the presynaptic modulatory effect of 1-norepinephrine (cf. refs. 17, 19, 26, 27 ) and 1-phenylephrine (5, 9) cannot simply be attributed to their direct effects on a2-adrenoceptors present on noradrenergic varicosities; an indirect component must also be involved in these actions.
The release of 1-phenylephrine is not subject to presynaptic modulation; yohimbine, an a2-adrenoceptor antagonist, failed to influence it. In addition, it is interesting to note that the tyramine-induced release is also not affected by a2-adrenoceptor blocking agents (28) .
In the present experiments, we found that endogenous norepinephrine released by 1-norepinephrine and 1-phenylephrine reached a concentration in the vicinity of the axon terminals (where presynaptic modulation of norepinephrine release evoked by axon stimulation takes place) high enough to inhibit further stimulation-induced release via presynaptic a2-adrenoceptors. This is substantiated by the findings that 1-norepinephrine and 1-phenylephrine enhance the spontaneous release of radioactivity but actually inhibit the stimulation-evoked release of [3W]norepinephrine. Several unexpected effects of 1-phenylephrine have been reported (9, 29-34)-for example, P-adrenoceptor (35, 36)-and a-adrenoceptor (5)-mediated positive inotropic effects. These could be explained by our finding that 1-phenylephrine releases endogenous norepinephrine, which may contribute to the response of the effector cells. The concentration of endogenous norepinephrine released in a Ca-independent manner into the vicinity of release sites may be high enough to inhibit the release of norepinephrine in response to axonal stimulation (Ca-dependent release). It is suggested, therefore, that this indirect effect of 1-phenylephrine (or 1-norepinephrine) may be partly or fully responsible for the pharmacological effects of added 1-norepinephrine or 1-phenylephrine or for the physiological effect of locally released or circulating norepinephrine and adrenaline. If, under physiological conditions, the norepinephrine released in a Ca-dependent fashion releases additional norepinephrine in a Ca-independent manner (Fig. 4) , the target cells will not be able to distinguish between norepinephrine of different rine concentration is sufficiently high, it may produce a further release of norepinephrine from the varicosities but in a Ca-independent way (Ca-). The Ca-independent release of norepinephrine is of cytoplasmic origin. The released norepinephrine diffuses locally and influences a large number of varicosity branches that are equipped with a2-adrenoceptors. Those boutons located distally from varicosities containing a2-adrenoceptors will not be invaded and therefore norepinephrine will not be released.
origins. Therefore, this release mechanism seems to be of both physiological and pharmacological significance.
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